4//SEC Filing
Sommadossi Jean-Pierre 4
Accession 0000950170-25-013846
CIK 0001593899other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 6:00 PM ET
Size
15.0 KB
Accession
0000950170-25-013846
Insider Transaction Report
Form 4
Sommadossi Jean-Pierre
DirectorPresident, CEO, and Chairman
Transactions
- Tax Payment
Common Stock
2025-01-31$3.06/sh−88,601$271,119→ 300,940 total - Exercise/Conversion
Restricted Stock Units
2025-01-31−173,467→ 173,466 total→ Common Stock (173,467 underlying) - Award
Stock Option (Right to Buy)
2025-01-31+440,000→ 440,000 totalExercise: $3.06Exp: 2035-01-30→ Common Stock (440,000 underlying) - Exercise/Conversion
Common Stock
2025-01-31+173,467→ 290,024 total - Award
Common Stock
2025-01-31+99,517→ 389,541 total - Award
Restricted Stock Units
2025-01-31+99,518→ 99,518 total→ Common Stock (99,518 underlying)
Holdings
- 5,866,025(indirect: By LLC)
Common Stock
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").
- [F3]The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
- [F4]Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.
- [F5]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.
Documents
Issuer
Atea Pharmaceuticals, Inc.
CIK 0001593899
Entity typeother
Related Parties
1- filerCIK 0001296995
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 6:00 PM ET
- Size
- 15.0 KB